A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Marvin J SklarSantina MaiolatesiNoelle PattersonMartha SedegahKeith LimbachNimfa Teneza-MoraIlin ChuangK Monique Hollis-PerryJo Glenna BananiaIvelese GuzmanHarini GaneshanSharina ReyesMichael R HollingdaleMimi WongAshley LindstromAnatalio ReyesYolanda AlcortaLindsey GarverKelli BankardArnel BelmonteMaria BelmonteJun HuangKalpana GowdaSandra InoueRachel VelascoElke Bergmann-LeitnerJack HutterTida LeeNehkonti AdamsSidhartha ChaudhuryDevin HuntCindy TammingaEleanor BerrieDuncan BellamyMustapha BittayeKatie J EwerCarter DiggsLorraine A SoissonAlison LawrieAdrian HillThomas L RichieEileen VillasanteJudith E EpsteinChristopher A DuplessisPublished in: PloS one (2021)
This study demonstrated that the ChAd63 CAT vaccine exhibited significant protective efficacy, and confirmed protection was afforded by adding a third antigen (T) to a two-antigen (CA) formulation to achieve increased VE. Although the ChAd63-CAT vaccine was associated with increased frequencies of systemic AEs compared to the CA vaccine and, historically, compared to the HuAd5 vectored malaria vaccine encoding CSP and AMA1, they were transient and associated with increased vector dosing.